Effects of brequinar sodium on cynomolgus monkeys: immunosuppression and pharmacokinetics.
Jaffee
B D
BD
Division of Inflammatory Diseases Research, Du Pont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0400.
Jones
E A
EA
Zajac
I
I
Magolda
R L
RL
Cramer
D V
DV
Makowka
L
L
D000284:Administration, Oral; D000818:Animals; D001713:Biphenyl Compounds / Q000097:blood / Q000493:pharmacokinetics / Q000494:pharmacology*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008252:Macaca fascicularis; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D014316:Tritium; D011798:Quinaldines
D001713:Biphenyl Compounds; D007166:Immunosuppressive Agents; D013936:Thymidine; D014316:Tritium; C046943:brequinar; D011798:Quinaldines